| Автор | Simon, David, G. |
| Дата выпуска | 1986 |
| dc.description | Expected costs and health outcomes associated with cadaveric kidney transplantation using cyclosporine (CsA) plus steroids, azathioprine (Aza) plus steroids, and "dialysis only" were estimated from both a societal perspective and a Medicare perspective. Published data on patient and graft survival and treatment costs were incorporated into a Markov model to predict the ten-year experience of hypothetical cohorts of 1000 35-year-old persons with end-stage renal disease (ESRD) exposed to each treatment option. In the base-case analysis conducted from the societal perspective, ten-year cumulative costs for the "dialysis only," CsA, and Aza cohorts were $181, $147, and $138 million, respectively. Transplantation using CsA rather than Aza would cost an estimated $19,800 per additional life-year and $9,700 per additional graft-year; whereas from Medicare's perspective, CsA would be less costly than Aza. This analysis suggests that under present regulations, widespread use of CsA instead of Aza for cadaveric graft recipients would result in significant cost shifting from Medicare to the private sector; but from a societal perspective, this would result in no, or at worst, relatively inconsequential, additional health expenditures. A policy whereby dollar savings achieved by Medicare from improved graft survival were used to help underwrite the cost of CsA for cadaveric kidney transplants would promote access to this drug and have little impact on the overall cost of care for individuals with ESRD. Key words: cost- effectiveness; cyclosporine; end-stage renal disease; cadaveric kidney transplantation; Med icare. (Med Decis Making 6:199-207, 1986) |
| Издатель | Sage Publications |
| Название | A Cost-effectiveness Analysis of Cyclosporine in Cadaveric Kidney Transplantation |
| Тип | Journal Article |
| DOI | 10.1177/0272989X8600600403 |
| Print ISSN | 0272-989X |
| Журнал | Medical Decision Making |
| Том | 6 |
| Первая страница | 199 |
| Последняя страница | 207 |
| Выпуск | 4 |
| Библиографическая ссылка | Aroesty J., Rettig R.: The cost effects of improved kidney transplantation. Santa Monica, CA, Rand Corporation, 1984 (Rand publication no. 3099-NIH/RC), p 14 |
| Библиографическая ссылка | Beck JR, Pauker SG: The Markov process in medical prognosis. Med Decis Making3:419-458, 1983 |
| Библиографическая ссылка | Calne RY, Wood AJ: Cyclosporin in cadaveric renal transplantation: 3-year follow-up of a European multicentre trial (letter). Lancet ii:548, 1985 |
| Библиографическая ссылка | The Canadian Multicentre Transplant Study Group: A randomized clinical trial of cyclosporin in cadaveric renal transplantation. N Engl J Med309:809-815, 1983 |
| Библиографическая ссылка | The CanadianMulticentre Transplant Study Group: A randomized trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med314:1219-1225, 1986 |
| Библиографическая ссылка | The Canadian Transplant Study Group: Estimation of parameters influencing the benefit:detriment ratio of cyclosporine in renal transplantation. Am J Kidney Dis5:328-332, 1985 |
| Библиографическая ссылка | Eggers PW: Trends in Medicare reimbursement for end-stage renal disease: 1974-1979. Health Care Fin Rev6(1):31-38, 1984 |
| Библиографическая ссылка | European Multicentre Trial Group: Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet2:986-989, 1983 |
| Библиографическая ссылка | Evans RW, Manninen DL, Garrison LP Jr, et al: The quality of life of patients with end-stage renal disease . N Engl J Med 312:553-559, 1985 |
| Библиографическая ссылка | Ferguson RM , Sommer BG: Cyclosporine (CsA) in renal transplantation: a single institution experience. Am J Kidney Dis 5:296-306, 1985 |
| Библиографическая ссылка | Gutman RA, Stead WW, Robinson RR: Physical activity and employment status of patients on maintenance dialysis . N Engl J Med 304:309-313, 1981 |
| Библиографическая ссылка | Hunsicker LG : The impact of cyclosporine on cadaveric renal transplantation: a summary statement. Am J Kidney Dis 5:335-341, 1985 |
| Библиографическая ссылка | Hutchinson TA, Thomas DC, MacGibbon B.: Predicting survival in adults with end-stage renal disease: an age equivalence index. Ann Intern Med96:417-423, 1982 |
| Библиографическая ссылка | Jacobs C., Broyer M., Brunner FP, et al: Combined report on regular dialysis and transplantation in Europe, XI, 1980. In: Robinson BHB, Hawkins JB, Davision AM (eds): Proceedings of the European Dialysis and Transplant Association (Paris) 18:25-26, 1981 |
| Библиографическая ссылка | Kahan BD, Kerman FH, Wideman CA, et al: Impact of cyclosporine on renal transplant practice at the University of Texas Medical School at Houston. Am J Kidney Dis5:288-295, 1985 |
| Библиографическая ссылка | Krakauer H. , Grauman JS, McMullan MR, et al: The recent U.S. experience in the treatment of end-stage renal disease by dialysis and transplantation. N Engl J Med 308:1558-1563, 1983 |
| Библиографическая ссылка | Matas AJ, Tellis BA, Veith FJ, et al: The fate of the patient returned to hemodialysis after losing a renal transplant. JAMA250:1053-1056, 1983 |
| Библиографическая ссылка | Milford EL, Kirkman RL, Tilney NL, et al: The clinical experience with cyclosporine and azathioprine at Brigham and Women's Hospital. Am J Kidney Dis5:313-317, 1985 |
| Библиографическая ссылка | Opelz G., Mickey MR, Terasaki PI: Calculations on long-term graft and patient survival in human kidney transplantation . Transplant Proc 9(1)27-30, 1977 |
| Библиографическая ссылка | Roberts SD, Maxwell DR, Gross TL: Cost effective care of end-stage renal disease: a billion dollar question . Ann Intern Med 92(Part 1):243-248, 1980 |
| Библиографическая ссылка | Stange PV, Sumner AT: Predicting treatment costs and life expectancy for end-stage renal disease . N Engl J Med 292:372-378, 1978 |
| Библиографическая ссылка | Stason WB, Weinstein MC: Allocation of resources to manage hypertension. N Engl J Med296:732-739, 1977 |
| Библиографическая ссылка | 98 Stat. 2339 (1984) |
| Библиографическая ссылка | Task Force on Organ Transplantation: Report to the Secretary and the Congress on Immunosuppressive Therapies, 1985 . U.S. Department of Health and Human Services |
| Библиографическая ссылка | U.S. Congress, Senate, Committee on Finance: Proposed prospective reimbursement rates for the end-stage renal disease (ESRD) program under Medicare (97th Cong., 2nd Sess., Committee Print). Washington, DC, U.S. Government Printing Office, 1982, pp 13-16 |
| Библиографическая ссылка | U.S. Department of Health and Human Services, Health Care Financing Administration: End-stage renal disease: annual report to Congress, 1981, p 69 |
| Библиографическая ссылка | U.S. Department of Health and Human Services. Health Care Financing Administration: Medicare program; prospective payments for Medicare inpatient hospital services. Federal Register49:34780-34796, Aug 31, 1984 |
| Библиографическая ссылка | Vollmer WM, Wahl PW, Blagg CR: Survival with dialysis and transplantation in patients with end-stage renal disease. N Engl J Med308:1553-1558, 1983 |
